Botanova ads scrutinized
This article was originally published in The Tan Sheet
The U.K. Medicines and Healthcare products Regulatory Agency upholds three advertising complaints filed last fall against German pharmaceutical company Pascoe Pharmazeutische Praparate GmbH. The complaints allege marketing for Botanova (St. John's wort, passion flower and valerian) misleads consumers. The British Herbal Medicine Association and Schwabe Pharma complained Pascoe ads inappropriately touted Botanova has improved efficacy over other products. The claims violate U.K. ad requirements for traditional herbal medicines. BHMA also complained that Botanova press materials incorrectly said the product is not associated with drug-drug interactions. Pascoe revised the materials and confirmed future marketing material will comply with the U.K. requirements for advertising of registered traditional herbal medicines, according to notices MHRA posted July 17
You may also be interested in...
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.
Tests used to detect cytomegalovirus in organ transplant patients may face an easier path to market under a proposed rule that the US Food and Drug Administration released on 18 September. See what the regulatory agency said about it here.
While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere.